Qurient Reports Mocaciclib Synergy With TOP1-Based ADCs in Science Advances Study / ADC resistance, ADCs, Antibody drug ...
Unraveling the Mechanisms Behind Allogeneic CAR-T Rejection and Expansion / Andrew P. Jallouk, Elvin J. Lauron, Emerie Danson ...
Jimmy Fund Walk Raises More Than $200 Million for Cancer Research / Benjamin Ebert, cancer, Cancer research, Dana-Farber ...
Bishal GyawaliÖ‰ Hematology-Oncology Care, Research, and Training in Nepal: Meet the First GPO Fellow / Bishal Gyawali, ...
Partners Unite to Advance AI-Supported Cancer Care at PATH Project Plenary / Andreas Charalambous, cancer, cancer care, ...
Yan LeyfmanÖ‰ What Determines Whether an Allogeneic CAR-T Product Succeeds or Gets Rejected? / cancer, CAR-T therapy, ...
Celebrating a Mentor Who Shaped a Journey in Oncology / Amit Oza, cancer, IGCS Conference, Ilaria Colombo, OncoDaily, ...
A patient can move into a higher-risk category through rising blasts, worsening cytopenias, adverse genetics, or a ...
Opportunity to Celebrate the Quiet Champions of Ovarian Cancer in Your Community - World Ovarian Cancer Coalition / cancer, ...
Excited to Have Been Selected for the 2027 EORTC Early Career Investigator Programme! / cancer, EORTC, Manuel Mazariegos Rubi ...
A Personal Reminder for Breast Cancer Awareness Month / Amanda Impellizzeri, Breast Cancer, breast cancer awareness month, ...
PACIFIC-R durvalumab data show 49.2% 5-year overall survival and 35.2% 5-year real-world PFS after chemoradiotherapy for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results